Apnimed Appoints Industry Veterans to Drive AD109 Growth
CAMBRIDGE, Mass., July 1, 2026 Apnimed has strengthened its executive leadership team with the appointments of Michael Kelly as...
oral therapy
Advertisement
AnaCardio Publishes AC01 Heart Failure Study in The Lancet
STOCKHOLM, Sweden, June 25, 2026 AnaCardio announced that results from its Phase 1b/2a GOAL-HF1 clinical trial evaluating AC01, a...
Belay Announces NCCN Recommendation for CSF-Based Profiling in High-Grade Gliomas
CHICAGO, Ill., June 20, 2026 The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology...
cAMPfield Launches With $180M to Advance Oral IBD Therapy
SAN DIEGO, Calif., June 20, 2026 cAMPfield Therapeutics has officially emerged from stealth with a $180 million Series A...
DKSH and BridgeBio Partner to Expand ATTR-CM Treatment Access
SINGAPORE, June 11, 2026 DKSH Healthcare and BridgeBio have entered into a strategic distribution and commercialization partnership aimed at...
Advertisements
Takeda’s Zasocitinib Outperforms Deucravacitinib in Psoriasis
STOCKHOLM, Sweden, June 11OSAKA, Japan and CAMBRIDGE, Massachusetts, June 11, 2026, 2026 Takeda has announced positive topline results from...
Septerna Initiates SEP-479 Phase 1 Hypoparathyroidism
SOUTH SAN FRANCISCO, Calif., April 13, 2026 Septerna, Inc. has announced the initiation of its Phase 1 clinical trial...
Enanta Pharma Advances EDP-978 Phase 1 Urticaria Drug
WATERTOWN, Mass., April 13, 2026 Enanta Pharmaceuticals, Inc. has announced the first participant dosing in its Phase 1 clinical...
TML-6 Advances to Global Phase 2 Alzheimer’s Trials
TAINAN, Taiwan, Feb. 9, 2026 — MerryLife Biomedical Inc. announced positive Phase 1 clinical findings for TML-6, its investigational...
Pharvaris Unveils Breakthrough Oral Therapy for HAE Relief
ZUG, Switzerland, November 10, 2025 — Pharvaris N.V. (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor...
Advertisement
